IC
CRBP icon

Intersect Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Intersect Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-484
Closed -$27K – 407
2021
Q2 		$27K Hold
484
– – ﹤0.01% 374
2021
Q1 		$29K Buy
+484
New +$31.8K 0.01% 336

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Intersect Capital's CRBP Position: Q3 2021 in Review

Intersect Capital sold out of Corbus Pharmaceuticals (CRBP) in Q3 2021, closing a stake of 484 shares — an estimated $27K sold.

Intersect Capital first reported a position in CRBP in Q1 2021 and held it in 2 quarters. The position peaked at $29K in Q1 2021. 85 funds tracked by Wall St. Rank hold CRBP as of Q3 2021.

  • Intersect Capital reported no remaining Corbus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Intersect Capital sold 484 Corbus Pharmaceuticals shares in Q3 2021, an estimated $27K.
  • Intersect Capital first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Intersect Capital's Corbus Pharmaceuticals position peaked at $29K in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2021.

Based on Intersect Capital's 13F filing for Q3 2021, filed 15 Oct 2021.